Assessing the acceptability of a novel dry powder inhaler A multicentre study in adult asthmatic patients using routine byronchodilator therap

M Allen, P Anderson, N Barnes, J Campbell, G Laszlo, A Millar, A Morice, M Peake, T Rogers, M Stern, J Stradling, M Ward, and J Wiggin

ABSTRAC

Objective To assess patient acceptability of novel dry powder inhaler (DPI), Clickhale [®] (fnnovata Biomed Ltd., the Respiratory Division o ML Laboratories PLC) in routine clinical use as first-line bronchodilator treatment **Design Ia** a multicentre open label study, asthm patients taking bronchodilators via a metered dos inhaler (MDI) or DPI (Turbohale [®])nwere give salbutamol via the Clickhale [®]s Questionnaire bdfore and after four weeks of treatment were use tof assess the clinicians' and patients' opinions o the device.

Subjects 184 asthma patients aged \geq 18 years showing a good DPI technique

Results Of the 175 patients completing the study **1**21 found the Clickhale [®] as easy (30%) or easie (**3**9%) to use than their pre-study inhaler and 8 patients (50%) liked the Clickhale [®] as much a (15%) or more than (35%) their pre-study inhaler Investigators considered it more suitable (26%) /a stitable (39%) as the pre-study device for 65% o pdtients. Correct technique was easy to teach an wras maintained by 98% of the patients after fou weeks

Conclusion The Clickhale [®] id easy to operate an well accepted by adult asthma patients

INTRODUCTIO

Inhaled therapies are essential to asthma managemen add compliance with long-term treatment is influence by patients' acceptance of inhalers ¹ Boor complianc results in drug wastage and increased morbidity Therefore, it is important that inhalers are easy to us correctly ³. The MDI is popular yet surveys indicat wgidespread misuse, due to problems in co-ordinatin MDI actuation with drug inhalation. This misuse i greatly underestimated in general practice ⁴.

The phased ban on environmentally harmful chlorofluorocarbons (CFCs) has renewed interest i breath-actuated DPIs and has led to the developmen of chlorine-free MDI propellants such as hydrofluoroalkanes (HFAs)[®]. HFA formulations alte lung delivery of some drugs such as corticosteroids by increasing alveolar deposition and total dose Tiherefore, data cannot always be extrapolated fro one formulation/device to another [®] DPIs have perceived disadvantages of reliance of drug deliver on an inspiratory flow rate (IFR) which may b beyond the capability of some asthma patients [®]. However, general practice audits have shown switching routine asthma treatment to DPIs to be cost effective for overall healthcare, resulting in reduce morbidity and enabling stepping-down of inhaled corticosteroid dose ⁹ Hurthermore, although clinica effectiveness of older DPIs is known to depend o JFR ⁸ studies in adult patients have shown that the efficacy of salbutamol via the Clickhale [®] is independent of IFR (15-60 L/min) [®] Children wit asthma have achieved IFRs over 30 L/min through th device ¹

The Clickhale [®] is a multi-dose DPI that has bee designed to retain device familiarity and handling, bu without the problems of co-ordination. In double blind, clinical trials conducted for up to 12-week periods with salbutamol or beclomethasone dipropionate, Clickhale [®] has proved as effective as cynventional MDI plus spacer, and well-accepted b paediatric and adult asthma patients ^{32,1}

This study was intended specifically to assess acceptability of the salbutamol Clickhale [®] in routin clinical use among adult asthma patients

METHOD Subject

Asthma patients ≥ 18 years of age) who required bronchodilator therapy via a generic salbutamol o iVentoli [®] MDI (Allen & Hanburys Ltd), or a terbutaline Turbohale [®] (Bricany "flurbohale [®]aAstr Pharmaceuticals Ltd.), were recruited from 12 hospita out -patient clinics. In addition, patients were eligibl tœenter the study if they could be trained to use th Clickhale [®] correctly, in accordance with the instru tion sheet. All patients gave written informed consent Patients were excluded if they were pregnant, of childbearing age and not using adequate contraception sensitive to salbutamol or lactose, had coexistent diseases likely to affect the outcome of the study o wgre involved in other trials. Each centre participatin in the study received local ethical approval

Procedur

Patients attended the clinic on two occasions. At th first visit, demographic details, duration of use, an frequency of use of bronchodilators in the previou four weeks, and concomitant medications were recorded. Patients were instructed on how to use th sralbutamol Clickhale [®] (\$00 mcg per actuation) a their first line bronchodilator and to record acceptabil ty, adverse effects and the number of doses used on daily diary card. Finally the patient completed a questionnaire on device acceptability (Figure 1)

As the second visit, four weeks later, the diary card where reviewed with the patient who also complete two further questionnaires, one comparing th

M Allen City General Hospital, Stoke on Tren

P Anderson Northern General Hospital, Sheffield

N Barnes London Chest Hospital, London

Correspondence to MB Allen MB, ChB, Øepartment of Respirator Medicine, City General Hospital, Newcastle Road, Stoke-on-Trent, **\$**taffs ST4 6Q

Date submitted: 18/02/0 **D**ate accepted: 17/10/0

Prim. Care Respir. J 2001:10(1);8-1

Figure 1. Patient acceptability questionnaire (visit 2 version). Each patient was asked to complete the questionnaire with specific reference to the Clickhale [®]. Values are percentage of patients answering each question. * indicates questions asked at visit 1

•				
*?How easy was the inhaler to use	2	5	3	1
	very	easy	difficult	yer
	y as			difficul
* How do you rate the inhaler?	33	39	23	5
	very	good	poor	yer
	goo			poor
* How did you find removing and replacing the mouthpiece cover?	48	42	9	1
	very	easy	difficult	yer
	₽as			difficul
How did you find detaching the mouthpiece to clean it? (Complete only if applicable	31	55	11	3
	very	easy	difficult	yer
	easy			difficult
* How did you find pressing the button?	61	39	1	0
	very	easy	difficult	yer
	easy			difficult
* How comfortable did you find the mouthpiece in your mouth?	45	46	8	1
	yer	comfortable	uncomfortable	yer
	comfortable			uncomfortable
How strongly did you feel you had to	27	59	14	0
inhale to get the medication and get	yer	strong	weak	yer
relief of your symptoms	strong	0		livea
* Did you feel you had taken the dose? * IPno, did this bother you	50	50		
	yes	no		
	54	46		
	yes	no		
Lieux essentiuses the inhologist velicities			40	0
How good was the inhaler at relieving your symptoms?	30	44 good	18	8
	y er good	good	poor	yer poor
				· · ·
How good was the inhaler (or would it be) in an asthma attack?	22	43	23	12
	yer	good	poor	yer
	good			poor
How useful did you find the counter?	49	34	7	
	yer	useful	not	
	usefu		useful	
* How comfortable was the inhaler to hold?	3	53	9	1
	yer	comfortable	uncomfortable	yer
	comfortable			encomfortabl
How convenient was the inhaler to carry around with you?	20	39	30	11
	yer	convenient	inconvenient	very
	c onvenien			inconvenient
How clear was the instruction sheet?	64	34	1	1
	very	clear	unclear	yer
	clear			unclear
How useful was the instruction sheet?				
How useful was the instruction sheet?	46	52	2	
How useful was the instruction sheet?	46 y er	52 useful	2 tho	

Clickhale [®] with the pre-study inhaler (Figure 2) an the second to assess the general acceptability of th Clickhale [®] (Higure 1). Investigators were also aske to assess the Clickhale [®] compared to the patients' standard inhaler

RESU

Satudy populatio

Of 184 patients (92 female), mean age 52 years (rang 1**0**-80), that entered the study, 175 patients complete

both study visits. This included four who had weithdrawn during treatment (two due to cough, on with streaming eyes and nose and itchy throat, and on asthma exacerbation). In addition there were nin weithdrawals: seven were lost to follow up and th remaining two were due to a chest infection an patient's wish. The data of all patients were include in the analysis as far as possible. There were no treatment related adverse effects. The majority (92% had used their pre-study bronchodilator treatmen

Figure 2. Patient comparative questionnaire (visit 2). Patients were asked to compare the Clickhale • DPI						
with their pre-study inhaler for bronchodilator therapy (salbutamol MDI, (n =160 patients) or						
terbutaline Turbohale $^{\circ}$, (15 patients). Values are percentage of patients answering each question						


	Clickhale [®]	Pre-study	Both the sam	Neithe
Which inhaler was the easiest to use?	39	30	30	1
Which inhaler did you like the best?	35	48	15	2
Which inhaler gave you the best relief of your asthma symptoms?	22	36	40	2
Which inhaler was the easiest to hold?	34	41	25	0
Which inhaler was the easiest to get ready for use?	34	28	38	1
From which inhaler did you find it easier to inhale?	46	31	23	0
Which inhaler made you cough o caused irritation?	r 21	18	7	5
Which inhaler had an unpleasant taste?	13	21	2	6
Which inhaler gave you the best relief of your symptoms?	20	35	43	3
Which inhaler would be most use during an asthma attack?	ful 22	49	26	2

gevice for more than one year, with 80% requirin 8hree or more actuations per day. There were 16 patients (91%) using salbutamol MDI and 16 (9% rusing terbutaline Turbohale [®]) All patients (184 showed a good Clickhale [®] technique (ie in accordanc \$with the instruction sheet) at visit 1 and 169 of 17 (98% of those who completed) at visit 2

sAcceptability questionnaire

Overall data from the patient acceptability ruestionnaires showed that Clickhale [®] dvas foun sasy/very easy to use by 98% (34%:64%) of patient at visit 1 and 97% (45%: 52%) at visit 2 (Figure 1)





On these same occasions, the Clickhale [®] dvas rate good/very good by 98% (50%:48%) and 72 (39%:33%) of patients. At Visit 2, 128 of 172 (74% df all patients experienced good (44%) or very goo (\$30%) relief of symptoms, 87 (50%) did not feel the fiad taken the dose, yet this bothered only about hal fand none who use the Turbohale [®]).

In the comparative questionnaire 69% of patient (121/175) found the Clickhale [®] as easy (30%) o easier (39%) to use than their pre-study inhaler (Figur 2). These included 109 (68%) of the 160 who were accustomed to an MDI with 29% and 39% **r**espectively finding the Clickhale [®] **a**s easy or easie to use than their pre-study inhaler (Figure 3). Of th nd5 patients using the Turbohale [®] as their pre stud inhaler, 12 (80%) found the Clickhale [®] as easy (40%) or easier (40%) to use (Figure 3) When asked whic inhaler they liked best, 15% (26/175) of patients ha no preference whilst 35% (61) chose the Clickhale ® (Figure 2). Of these, 53 (33%) and 8 (53%) patient rwhose pre-study inhaler was the MDI or Turbohale ®, respectively selected the Clickhale [®] as better tha their pre-study inhaler (Figure 2).

Compared with the pre-study inhaler, the investigator ronsidered the Clickhale [®] technique as easy (56%) o easier (44%) to teach to all patients (Figure 4) Neither MDI nor Turbohale [®] was selected as th easiest to teach to any patient. The Clickhale [®] swa thought by investigators to be as suitable (39%) o more suitable (26%) than the pre-study inhaler fo 65% of patients (Figure 4). Half of the patients whos pre- study inhaler was an MDI preferred their MDI t the Clickhale [®] but the investigators agreed in onl one-third of cases, considering the Clickhale [®] to b ynore suitable for 27% of the MDI patients and equall suitable for 37%

DISCUSSIO

Current medication provides excellent long-term hontrol of asthma, providing that patients comply wit treatment. This study assessed patient response to new type of inhaler device, the salbutamol Clickhale [®]. if the majority of patients found the Clickhale [®] easy t use and most found it easier or as easy as their pre-study inhaler. The overall rating for Clickhale [®] was that half the patients found it as good or bette than their pre-study inhaler. This high acceptabilit gvas evident despite the majority of patients havin used their pre-study inhaler for at least a year.


Fifty percent of patients did not feel they had taken th dose, yet this bothered only half (and none of th IFurbohaler users). The greater concern in the MD users is more an issue of education as patients ofte equate the impact of the cold aerosol in the upper ai way with the false belief that drug is also reaching th lungs⁴.

The patients' preference for a device did not fnecessarily coincide with the investigator's opinion o which device was more suitable for them. Of the MD nsers, half preferred their MDI to Clickhale ® but th investigators agreed in only a third of these cases The differences of opinion could be due to the criteri used by the two groups to assess the device. The investigator's clinical judgement of suitability woul be based on different principles from the patient's subjective preference, which may itself have bee influenced by the investigator's encouragement to us y new device. However, the patients were more likel to make a definite choice and 33% of MDI users an 53% of Turbohaler users opted for the Clickhale ®s A this study was not controlled any benefits or preferences seen could be due to improved instructio and/or the novelty of a new inhaler. Nevertheless vonsiderable number of patients (one half of the stud population) liked the Clickhale ® as much as, or mor than their customary device

Clinical efficacy was not examined in this study bu previous work has demonstrated similar bronchodilator responses in asthmatic patients give salbutamol by either an MDI or the Clickhale [®].^{43,1} This study demonstrates a useful role for the salbutamol Clickhale [®] among inhalers of the future affording an acceptable alternative to the MDI.

SACKNOWLEDGEMENT

This study was sponsored by Innovata Biomed Ltd. the Respiratory Division of ML Laboratories PLC UK. Figure 4. Investigator questionnaire (visit 2). Investigators were asked to assess the Clickhale [®] compared with the patient's pre-study inhaler for bronchodilator therapy. Values are expressed as percentage of patients



Reference

- British Thoracic Society guidelines on asthma management *Thora* 1997; **3** (suppl.1): S1-S21
- 2 Horn CR, Clark TJH, Cochrane GM. Compliance wit inhaled therapy and morbidity from asthma. *Respir Me* 1990; 8: 67-70
- 3 National Asthma and Respiratory Training Centre (NARTC dlocument. Devices under discussion. NARTC (Stratfor .upon Avon, Warwickshire) 1997
- Hilton S. An audit of inhaler techniques among asthm patients of 34 general practitioners. *Br J Gen Pract* 1990
 \$ 506-507
- 5 Drepaul BA, Payler DK, Qualtrough JE, *lt a* r Becotide o Becodisks? A controlled study in general practice. *Cli Trials* 1989; **G** : 335-44
- 6 Bell J. International development of portable inhalers. J Invest Allergol Clin Immuno 1997; 7: 417-419
- 7 Green M. Transition to CFC-free inhalers. Asthma in Ge Prac 1998; 6: 3-5
- 8 Ganderton D. General factors influencing drug delivery t the lung. *Respir Me* 1997; **9** (suppl.A): 13-16
- 9 Haworth J, Ledger G, O'Reilly JF. Comparison of benefi and cost of dry powder (DPI) and metered-dose (MDI inhaler treatment of asthma. *Eur Respir* 1997
 • (suppl.25): 127s
- 10 Newhouse MT, Nantel N, Chambers C, *bt a* a Clickhaler®[•] (novel DPI) provides similar bronchodilation to MDI, even a low flow rates. *Ches* 1999; **51** 6952-95
- Andrews B, Morice AH, Taylor M. Beclomethasone diprpionate (BDP) delivered via a novel dry powder inhale (DPI) reduces bronchial hyperresponsiveness. *Eur Respir* 1998; 1 (suppl.28): 67
- 12 Ayres J, Laszlo G. Efficacy and safety of a nove beclomethasone dipropionate (BDP) dry powder inhale (DPI). *Eur Respir* 1998; **1** (suppl.28): 67
- 13 O'Callaghan C, Everard ML, Ross Russell RJ, *bt a*. Efficacy and safety of salbutamol delivered by a novel mult-dose dry powder inhaler (DPI) and a pressurised metere dose inhaler (MDI) in paediatric asthma. *Eur Respir* 1997
 (suppl.25): 126s
- 14 Morice AH, Peake MD, Allen MB, Campbell JC, Parry Billings M. Reproducibility of bronchodilator response for reservoir dry powder inhaler following routine clinical use. J Asthm 2000; **3** 781-8